- Romero del Rincón, Celia|||0000-0002-0339-6616
- Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
- Quintas, Sonia|||0000-0003-0622-8228
- Garcia Azorin, David|||0000-0002-3132-1064
- Fernández-Lázaro, Iris|||0009-0004-2544-5206
- Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
- González Osorio, Yésica|||0000-0003-1461-9798
- Santos Lasaosa, Sonia|||0000-0002-4141-7705
- González Oria, Carmen
- Sánchez Rodríguez, Norberto
- Iglesias Díez, Fernando
- Echavarría Íñiguez, Ana|||0000-0001-7038-2911
- Gil Luque, Sendoa
- Huerta, Mariano|||0000-0003-0181-5335
- Campoy Diaz, Sergio|||0000-0002-8135-4139
- Muñoz-Vendrell, Albert|||0000-0001-8221-865X
- Lozano Ros, Alberto|||0000-0002-5186-8657
- Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
- Velasco Juanes, Fernando
- Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
- Echeverría, Amaya|||0000-0001-9225-5323
- Rodríguez-Vico, Jaime|||0000-0001-9360-5444
- Jaimes Sánchez, Alex
- Gómez García, Andrea
- Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
- Belvís, Roberto|||0000-0002-2137-180X
- Navarro Pérez, María Pilar|||0000-0001-6370-218X
- García-Moncó, Juan Carlos
- Álvarez Escudero, María Rocío
- Montes, Nuria
- Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.